TW200720256A - IL-12 modulatory compounds - Google Patents
IL-12 modulatory compoundsInfo
- Publication number
- TW200720256A TW200720256A TW095116858A TW95116858A TW200720256A TW 200720256 A TW200720256 A TW 200720256A TW 095116858 A TW095116858 A TW 095116858A TW 95116858 A TW95116858 A TW 95116858A TW 200720256 A TW200720256 A TW 200720256A
- Authority
- TW
- Taiwan
- Prior art keywords
- compounds
- modulatory compounds
- methods
- compositions
- hydrazone compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- -1 cyclic hydrazone compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000019734 interleukin-12 production Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68072405P | 2005-05-13 | 2005-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200720256A true TW200720256A (en) | 2007-06-01 |
Family
ID=37431562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095116858A TW200720256A (en) | 2005-05-13 | 2006-05-12 | IL-12 modulatory compounds |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US7863270B2 (zh) |
| TW (1) | TW200720256A (zh) |
| WO (1) | WO2006124662A1 (zh) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032493A1 (en) * | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| CA2635997A1 (en) * | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Morpholino pyrimidine derivatives and their use in therapy |
| EP2057129A1 (en) * | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| JP5534811B2 (ja) * | 2006-08-24 | 2014-07-02 | アストラゼネカ アクチボラグ | 増殖性疾患の治療に有用なモルホリノピリミジン誘導体 |
| EP2129219A4 (en) * | 2007-02-16 | 2012-08-29 | Synta Pharmaceuticals Corp | SUBSTITUTED FUSED CYCLE COMPOUNDS USED IN CASES OF INFLAMMATION OR IMMUNE DISORDERS |
| US8138183B2 (en) | 2007-07-09 | 2012-03-20 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
| WO2009100406A2 (en) * | 2008-02-07 | 2009-08-13 | Synta Pharmaceuticals Corp. | Topical formulations for the treatment of psoriasis |
| JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
| JPWO2011078221A1 (ja) | 2009-12-24 | 2013-05-09 | 味の素株式会社 | イミダゾピリダジン化合物 |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| EP2700409A1 (en) * | 2012-08-23 | 2014-02-26 | Deutsches Rheuma-Forschungszentrum Berlin | IL-27 for modulation of immune response in acute lung disease |
| JP6855243B2 (ja) | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| RU2709205C2 (ru) * | 2014-10-10 | 2019-12-17 | Прометик Фарма Смт Лимитед | Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза |
| JP6700638B2 (ja) * | 2014-10-10 | 2020-05-27 | リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ | 骨粗しょう症の予防及び治療用のフェニルケトンカルボキシレート化合物ならびに医薬組成物 |
| WO2016073877A1 (en) | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| WO2016073871A1 (en) * | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of melanoma |
| WO2016118709A1 (en) | 2015-01-23 | 2016-07-28 | Lam Therapeutics, Inc. | Anti-viral compositions containing pikfyve inhibitors and use thereof |
| US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| JP2019528305A (ja) | 2016-08-25 | 2019-10-10 | エイアイ・セラピューティクス・インコーポレーテッド | ＰＩＫｆｙｖｅ阻害薬を含む組成物およびＲＡＮＫシグナル伝達の阻害に関連する方法 |
| CN110167559A (zh) | 2016-10-12 | 2019-08-23 | 人工智能治疗公司 | 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法 |
| US10702534B2 (en) | 2017-03-31 | 2020-07-07 | AI Therapeutics, Inc. | Compositions and methods relating to the radioprotective effects of apilimod |
| JP7354123B2 (ja) | 2018-02-21 | 2023-10-02 | エイアイ・セラピューティクス・インコーポレーテッド | アピリモドとグルタミン酸作動薬を用いた併用療法 |
| WO2021051135A1 (en) | 2019-09-12 | 2021-03-18 | AI Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
| US20210244743A1 (en) | 2020-02-07 | 2021-08-12 | Al Therapeutics, Inc. | Anti-viral compositions and methods of use |
| EP4351585A1 (en) | 2021-06-11 | 2024-04-17 | Orphai Therapeutics Inc. | Stabilized apilimod compositions and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6384032B1 (en) * | 1999-06-17 | 2002-05-07 | Shionogi Bioresearch Corp. | Inhibitors of IL-12 production |
-
2006
- 2006-05-12 TW TW095116858A patent/TW200720256A/zh unknown
- 2006-05-12 WO PCT/US2006/018528 patent/WO2006124662A1/en not_active Ceased
- 2006-05-12 US US11/433,603 patent/US7863270B2/en active Active
-
2010
- 2010-12-23 US US12/978,356 patent/US8263764B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20060281711A1 (en) | 2006-12-14 |
| WO2006124662A1 (en) | 2006-11-23 |
| US20110294798A1 (en) | 2011-12-01 |
| US7863270B2 (en) | 2011-01-04 |
| US8263764B2 (en) | 2012-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200720256A (en) | IL-12 modulatory compounds | |
| TW200628159A (en) | IL-12 modulatory compounds | |
| TW200628463A (en) | Heteroaryl compounds | |
| TW200603798A (en) | Disalt inhibitors of il-12 production | |
| UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
| WO2005056759A3 (en) | Methods of generating variant proteins with increased host string content and compositions thereof | |
| TW200610528A (en) | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| MY150538A (en) | Process for the manufacture of dihydropteridinones | |
| NO20074823L (no) | Rasagilin-formuleringer med forbedret innholdsensartethet | |
| NO20090596L (no) | Antivirale fosfinatforbindelser | |
| MX343042B (es) | Compuestos heteroarilicos biciclicos. | |
| PL1836169T3 (pl) | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek | |
| MX2009004862A (es) | Estabilizacion de vacunas por liofilizacion. | |
| TW200628428A (en) | High calcium fertilizer composition | |
| TW200722079A (en) | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein | |
| MX2009005935A (es) | Compuestos biciclicos y su uso como anti-diabeticos. | |
| MY173526A (en) | Novel anti-?5?1 antibodies and uses thereof | |
| TW200714277A (en) | Methods and compositions for altering cell fuction | |
| NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
| MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
| TW200730518A (en) | Crystalline forms of docetaxel and processes for their preparation | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| TW200720232A (en) | Crystalline solid forms of tigecycline and methods of preparing same | |
| EP2129672A4 (en) | ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE | |
| WO2008033556A3 (en) | High pressure treatment of proteins for reduced immunogenicity |